1 University of California-San Francisco School of Medicine, San Francisco, CA.
2 Department of Radiology, Division of Neuroradiology, New York-Presbyterian Hospital, Weill Cornell Medicine, 525 E 68th St, Starr Pavilion, Box 141, New York, NY 10065.
AJR Am J Roentgenol. 2019 Apr;212(4):883-891. doi: 10.2214/AJR.18.20531. Epub 2019 Feb 19.
Both F-FDG PET and perfusion MRI are commonly used techniques for posttreatment glioma surveillance. Using integrated PET-MRI, we assessed the rate of discordance between simultaneously acquired FDG PET images and dynamic contrast-enhanced (DCE) perfusion MR images and determined whether tumor genetics predicts discordance.
Forty-one consecutive patients with high-grade gliomas (20 with grade IV gliomas and 21 with grade III gliomas) underwent a standardized tumor protocol performed using an integrated 3-T PET-MRI scanner. Quantitative measures of standardized uptake value, plasma volume, and permeability were obtained from segmented whole-tumor volumes of interest and targeted ROIs. ROC curve analysis and the Youden index were used to identify optimal cutoffs for FDG PET and DCE-MRI. Two-by-two contingency tables and percent agreement were used to assess accuracy and concordance. Twenty-six patients (63%) from the cohort underwent next-generation sequencing for tumor genetics.
The best-performing FDG PET and DCE-MRI cutoffs achieved sensitivities of 94% and 91%, respectively; specificities of 56% and 89%, respectively; and accuracies of 80% and 83%, respectively. FDG PET and DCE-MRI findings were discordant for 11 patients (27%), with DCE-MRI findings correct for six of these patients (55%). Tumor grade, tumor volume, bevacizumab exposure, and time since radiation predicted discordance between FDG PET and DCE-MRI findings, with an ROC AUC value of 0.78. Isocitrate dehydrogenase gene and receptor tyrosine kinase gene pathway mutations increased the ROC AUC value to 0.83.
FDG PET and DCE-MRI show comparable accuracy and sensitivity in identifying tumor progression. These modalities were shown to have discordant findings for more than a quarter of the patients assessed. Tumor genetics may contribute to perfusion-metabolism discordance, warranting further investigation.
正电子发射断层扫描(PET)和灌注磁共振成像(MRI)均常用于胶质瘤治疗后监测。本研究采用一体化 PET-MRI,评估同时获取的 18F-氟代脱氧葡萄糖(FDG)PET 图像与动态对比增强(DCE)灌注 MRI 图像之间的不相符率,并确定肿瘤遗传学是否可以预测不相符率。
41 例高级别胶质瘤患者(20 例 4 级胶质瘤和 21 例 3 级胶质瘤)采用一体化 3T PET-MRI 扫描仪进行标准化肿瘤方案检查。从全肿瘤感兴趣区和靶向 ROI 中获得标准化摄取值、血浆容积和通透性的定量测量值。采用 ROC 曲线分析和 Youden 指数确定 FDG PET 和 DCE-MRI 的最佳截断值。采用四格表和百分比一致性评估准确性和一致性。队列中有 26 例患者(63%)接受了肿瘤遗传学的下一代测序。
最佳的 FDG PET 和 DCE-MRI 截断值的灵敏度分别为 94%和 91%,特异度分别为 56%和 89%,准确性分别为 80%和 83%。11 例患者(27%)的 FDG PET 和 DCE-MRI 检查结果不一致,其中 6 例(55%)DCE-MRI 检查结果正确。肿瘤分级、肿瘤体积、贝伐单抗暴露和放疗后时间可预测 FDG PET 和 DCE-MRI 检查结果的不相符,ROC 曲线 AUC 值为 0.78。异柠檬酸脱氢酶基因突变和受体酪氨酸激酶基因突变增加了 ROC AUC 值至 0.83。
FDG PET 和 DCE-MRI 在识别肿瘤进展方面具有相当的准确性和灵敏度。这两种方法在评估的患者中,有超过四分之一的患者结果不一致。肿瘤遗传学可能导致灌注代谢不相符,需要进一步研究。